Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A

Melissa Bou Jaoudeh • 11 Jul 2022
ISTH 2022
Hemophilia Antibodies Emicizumab

Melissa Bou Jaoudeh, PhD, Sorbonne University, Paris, France, discusses some of the current challenges in the field of hemophilia, explaining that it is important to define better guidelines about the use of emicizumab, as well as to develop more efficient therapeutics with extended half-lives for patients with hemophilia A. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Melissa Bou Jaoudeh

Therapeutic potential of IdeS in hemophilia A with inhibitors
1:39
Therapeutic potential of IdeS in hemophilia A with inhibitors
Melissa Bou Jaoudeh • 11 Jul 2022
The impact of hemophilia inhibitors on patient outcomes
2:27
The impact of hemophilia inhibitors on patient outcomes
Melissa Bou Jaoudeh • 11 Jul 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals